Optimizing treatment for HER2-positive HR-positive breast cancer

被引：3

作者：

Debien, Veronique ^{[1
]}

de Azambuja, Evandro ^{[1
]}

Piccart-Gebhart, Martine ^{[2
,3
]}

机构：

[1] Univ Libre Bruxelles ULB, Hop Univ Bruxelles HUB, Inst Jules Bordet, Acad Trials Promoting Team, Brussels, Belgium

[2] Univ Libre Bruxelles ULB, Hop Univ Bruxelles HUB, Inst Jules Bordet, Brussels, Belgium

[3] Univ Libre Bruxelles, Inst Jules Bordet, Med Oncol Dept, Rue Meylemeersch 90, B-1070 Anderlecht, Belgium

来源：

CANCER TREATMENT REVIEWS | 2023年 / 115卷

关键词：

HER2-positive breast cancer; Anti-HER2; therapy; Monoclonal antibody; Tyrosine kinase inhibitor; Antibody -drug conjugate; Endocrine therapy; Clinical trials; Biomarkers; GROWTH-FACTOR RECEPTOR; OPEN-LABEL; TRASTUZUMAB EMTANSINE; DOUBLE-BLIND; PHASE-III; ESTROGEN-RECEPTOR; ENDOCRINE THERAPY; RANDOMIZED MULTICENTER; ADJUVANT CHEMOTHERAPY; TAMOXIFEN RESISTANCE;

D O I：

10.1016/j.ctrv.2023.102529

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Triple-positive breast tumors overexpress human epidermal growth factor receptor 2 (HER2) and are positive for hormone receptor (HR) expression. Data from real-life and clinical trials show that estrogen receptor (ER) expression affects the response to combinations of anti-HER2 and associated systemic therapies. Despite triple -positive tumors having decreased response rates compared to HR-negative/HER2-positive breast cancers, opti-mizing anti-HER2 treatment with dual anti-HER2 blockade remains important for optimal disease control. Preclinical data on the cross-talk between ER and growth factor receptor pathways show the efficacy of com-binations of endocrine therapy and anti-HER2 drugs, which is confirmed in the clinic. Molecular dissection of triple-positive breast cancer might provide the rational for additional therapeutic strategies and the identification of promising biomarkers. This review summarizes data on systemic treatment efficacy from major clinical trials and perspectives for future clinical research in triple-positive breast cancer.

引用

页数：16

共 50 条

[1] Optimizing Treatment of HER2-Positive Breast Cancer
Gradishar, William J.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2015, 13 (5.5): : 649 - 651
[2] Retrospective single case reports on the treatment of patients with HER2-positive/HR-positive early breast cancer with neratinib (IRENE)
Tribian, N.
Goehler, T.
Baesecke, J.
Guth, D.
Vannier, C.
Petru, E.
Maass, N.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 171 - 171
[3] Optimizing treatment of HER2-positive metastatic breast cancer
Jones, AL
Leyland-Jones, B
SEMINARS IN ONCOLOGY, 2004, 31 (05) : 29 - 34
[4] Characterization of the tumor immune microenvironment (TME) in early stage HR-positive HER2-positive breast cancer
Fenn, Kathleen M.
Marks, Douglas K.
Vanguri, Rami
Boboila, Shuobo
Guo, Hua
Hibshoosh, Hanina
Kalinsky, Kevin
Connolly, Eileen
CANCER RESEARCH, 2020, 80 (04)
[5] Optimizing (neo) adjuvant treatment of HER2-positive breast cancer
Basho, Reva K.
McArthur, Heather L.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10 : 1 - 13
[6] Ribociclib in HR-positive, HER2-negative breast cancer
Burki, Talha Khan
LANCET ONCOLOGY, 2016, 17 (11): : E482 - E482
[7] Complete response to pyrotinib combined with letrozole as first-line treatment of HER2-positive/HR-positive breast cancer: a case report
Xie, Ning
Liu, Liping
Tian, Can
Hu, Zheyu
Ouyang, Quchang
ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (16)
[8] Treatment of HER2-positive breast cancer
Figueroa-Magalhaes, Maria Cristina
Jelovac, Danijela
Connolly, Roisin M.
Wolff, Antonio C.
BREAST, 2014, 23 (02): : 128 - 136
[9] Updates to the Management of HR-Positive, HER2-Negative Breast Cancer
Gradishar, William J.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2024, 22
[10] Role of everolimus in the treatment of metastatic HER2-negative/HR-positive breast cancer
Pronzato, Paolo
FUTURE ONCOLOGY, 2017, 13 (16) : 1371 - 1384

← 1 2 3 4 5 →